UPDATE 2-Zafgen to scrap lead obesity drug, shares slide

July 19 (Reuters) - Zafgen Inc said it was
suspending the development of its lead obesity drug, beloranib,
more than six months after the U.S. Food and Drug Administration
asked the company to halt...